| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
|
J Natl Cancer Inst
|
2006
|
14.60
|
|
2
|
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
|
J Clin Oncol
|
2007
|
8.65
|
|
3
|
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
|
Clin Cancer Res
|
2008
|
5.88
|
|
4
|
Identification of molecular apocrine breast tumours by microarray analysis.
|
Oncogene
|
2005
|
5.27
|
|
5
|
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
|
J Clin Oncol
|
2009
|
4.05
|
|
6
|
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
|
J Clin Oncol
|
2008
|
3.23
|
|
7
|
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
|
Proc Natl Acad Sci U S A
|
2010
|
2.79
|
|
8
|
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.
|
J Clin Invest
|
2013
|
2.18
|
|
9
|
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
|
Lancet Oncol
|
2011
|
2.01
|
|
10
|
DNA methylation profiling reveals a predominant immune component in breast cancers.
|
EMBO Mol Med
|
2011
|
1.81
|
|
11
|
HER2-positive circulating tumor cells in breast cancer.
|
PLoS One
|
2011
|
1.73
|
|
12
|
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
Clin Cancer Res
|
2002
|
1.53
|
|
13
|
Multifactorial approach to predicting resistance to anthracyclines.
|
J Clin Oncol
|
2011
|
1.52
|
|
14
|
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.
|
Clin Breast Cancer
|
2004
|
1.46
|
|
15
|
The role of the pathologist in tissue banking: European Consensus Expert Group Report.
|
Virchows Arch
|
2010
|
1.44
|
|
16
|
Axillary recurrence rate in breast cancer patients with negative sentinel lymph node biopsy or containing micrometastases and without further lymphadenectomy: a monocentric review of 8 years and 481 cases.
|
Breast J
|
2011
|
1.37
|
|
17
|
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
|
Mol Cancer Ther
|
2004
|
1.17
|
|
18
|
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
|
Clin Cancer Res
|
2005
|
1.13
|
|
19
|
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
|
Clin Breast Cancer
|
2002
|
1.11
|
|
20
|
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.
|
BMC Genomics
|
2009
|
1.05
|
|
21
|
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.
|
Clin Cancer Res
|
2012
|
1.03
|
|
22
|
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
|
Mol Cancer Ther
|
2006
|
1.03
|
|
23
|
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
|
Clin Cancer Res
|
2008
|
1.02
|
|
24
|
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
|
Breast Cancer Res Treat
|
2007
|
1.02
|
|
25
|
Processed pseudogenes acquired somatically during cancer development.
|
Nat Commun
|
2014
|
1.00
|
|
26
|
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
|
Diagn Mol Pathol
|
2009
|
0.97
|
|
27
|
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.
|
Int J Cancer
|
2006
|
0.97
|
|
28
|
Bringing molecular prognosis and prediction to the clinic.
|
Clin Breast Cancer
|
2005
|
0.95
|
|
29
|
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
|
Breast Cancer Res Treat
|
2008
|
0.95
|
|
30
|
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
|
Eur J Cancer
|
2007
|
0.94
|
|
31
|
High-risk human papillomavirus infection in HIV-positive African women living in Europe.
|
J Int AIDS Soc
|
2013
|
0.91
|
|
32
|
Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
|
Eur J Cancer
|
2008
|
0.90
|
|
33
|
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
|
Breast Cancer Res
|
2012
|
0.90
|
|
34
|
Near total thyroidectomy is an optimal treatment for graves' disease.
|
Eur Arch Otorhinolaryngol
|
2009
|
0.89
|
|
35
|
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
|
BMC Genomics
|
2014
|
0.88
|
|
36
|
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.
|
Int J Clin Oncol
|
2002
|
0.88
|
|
37
|
Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS).
|
PLoS One
|
2010
|
0.85
|
|
38
|
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
|
Semin Oncol
|
2005
|
0.84
|
|
39
|
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
|
J Infect Dis
|
2013
|
0.84
|
|
40
|
Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres.
|
Clin Nucl Med
|
2008
|
0.83
|
|
41
|
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.
|
Breast Cancer Res Treat
|
2002
|
0.83
|
|
42
|
Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.
|
PLoS One
|
2013
|
0.83
|
|
43
|
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery.
|
Med Sci Monit
|
2007
|
0.83
|
|
44
|
Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).
|
Breast J
|
2011
|
0.82
|
|
45
|
Pathology as the cornerstone of human tissue banking: European consensus expert group report.
|
Biopreserv Biobank
|
2009
|
0.81
|
|
46
|
Lymphoscintigraphy in angiomyomatous hamartomas and primary lower limb lymphedema.
|
Clin Nucl Med
|
2009
|
0.80
|
|
47
|
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.
|
PLoS One
|
2013
|
0.80
|
|
48
|
Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment.
|
Analyst
|
2014
|
0.79
|
|
49
|
Molecular characterization of breast cancer cell lines by a low-density microarray.
|
Int J Oncol
|
2005
|
0.78
|
|
50
|
Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
|
Urol Int
|
2011
|
0.78
|
|
51
|
Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment.
|
Curr Pharm Des
|
2011
|
0.76
|
|
52
|
Fluorescence Imaging After Indocyanine Green Injection for Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery for Peritoneal Carcinomatosis From Colorectal Cancer: A Pilot Study.
|
Ann Surg
|
2016
|
0.76
|
|
53
|
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
|
Future Oncol
|
2013
|
0.75
|
|
54
|
Fluorescence Imaging After Indocyanine Green Injection for Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery for Peritoneal Carcinomatosis From Colorectal Cancer: A Pilot Study.
|
Ann Surg
|
2016
|
0.75
|
|
55
|
Eighteen months clinical experience with the GeneSearch breast lymph node assay.
|
Am J Surg
|
2009
|
0.75
|
|
56
|
Acute increase in goiter size during a normal pregnancy: an exceptional case report.
|
Thyroid
|
2003
|
0.75
|
|
57
|
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
|
Adv Anat Pathol
|
2017
|
0.75
|
|
58
|
Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells after oligomycin treatment.
|
Steroids
|
2003
|
0.75
|
|
59
|
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
|
Adv Anat Pathol
|
2017
|
0.75
|
|
60
|
Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.
|
Nat Commun
|
2017
|
0.75
|
|
61
|
Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors.
|
Acta Cytol
|
2015
|
0.75
|
|
62
|
Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature.
|
Int J Gynecol Pathol
|
2017
|
0.75
|